Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others believe these drugs are dangerous for patients. The post Hims & Hers vs. Novo Nordisk: Are Compounded GLP-1s Safe? appeared first on MedCity News.
BridgeBio Pharma’s approval of Beyonttra comes three months after the drug landed FDA approval for cardiomyopathy caused by transthyretin amyloidosis. Our recap of recent regulatory news also spans approvals in cancer, immunology, vaccines, and more. The post On Heels of FDA Nod, BridgeBio’s Rival to Blockbuster Pfizer Drug Wins European Approval appeared first on MedCity…
The distinction between value-based care and value-based payment isn’t merely semantic — it represents a crucial fork in the road for healthcare delivery. As AI and other technologies become more prevalent in healthcare, we must ensure they’re deployed in service of improving patient care rather than merely optimizing revenue. The post The Dark Side of…
For too long, the behavioral health industry has lacked the accountability mechanisms required to deliver on the high quality care that patients deserve. Provider organizations are proving day in, day out that when strong accountability becomes the standard, patients benefit, and the system as a whole grows stronger. The post It’s Time for Health Plans…
Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million. Meanwhile, Pfizer continued the culling of its gene therapies with the discontinuation of Beqvez for hemophilia B. The post Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity appeared first on MedCity News.
Hospitals are adopting AI technology more than ever before, but they still face challenges when it comes to measuring the impact of these solutions and scaling them, noted Kiran Mysore, chief data & analytics officer at Sutter Health. The post Hospitals Are Adopting AI — But Can They Measure and Scale These Tools? appeared first…
Future Family launched a nationwide IVF insurance product on Wednesday. If families don’t achieve a live birth after two cycles of IVF, they can get their money back. The post Future Family Guarantees ‘Baby or Your Money Back’ with New Nationwide IVF Insurance appeared first on MedCity News.
The conversations in Nashville reinforced the idea that while innovation remains essential, vendors must navigate the fine balance between bold ideas and real-world implementation, demonstrating not just promise but tangible outcomes. The post ViVE 2025: The Crossroads of Digital Health Innovation and Realities appeared first on MedCity News.
Blood centers are neutral partners, as they do not compete with hospitals for patients. Instead, they complement hospitals by providing a focused array of high-quality, specialized, patient-centric services, allowing hospitals to maintain primary relationships with patients and their families. The post Blood Centers Complement Hospitals to Drive Cell and Gene Therapy Access appeared first on…
This year’s ViVE conference was full of announcements — from acquisitions to rebrands to product launches. This list compiles short summaries for seven of the conference’s most notable announcements. The post 7 ViVE Announcements You Don’t Want to Miss appeared first on MedCity News.